This episode focuses on Hepatitis D (HDV), which is less common than hepatitis B or C but is a serious disease that often affects underprivileged and vulnerable populations. HDV has long been neglected and even though it is a highly aggressive viral hepatitis which can rapidly progress to cirrhosis and liver cancer, it remains under-recognised, underestimated, and under-treated. What is the status of Hepatitis D elimination globally and what challenges do we still face? Which strategies would be best deployed against Hepatitis D? How can lessons learned about Hepatitis C elimination be applied to Hepatitis Delta?
The EASL Policy Dialogues are supported by CymaBay, Echosens, Grifols and Novo Nordisk. CymaBay, Echosens, Grifols and Novo Nordisk have had no input into the content of the EASL Policy Dialogues.